

07/13/2006 10748085b.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/Caplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/Caplus and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/Caplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI
NEWS 14 JUL 11 CHEMSAFE reloaded and enhanced

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:02:56 ON 13 JUL 2006

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

07/13/2006 10748085b.trn

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:03:06 ON 13 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2006 HIGHEST RN 892389-74-1
DICTIONARY FILE UPDATES: 12 JUL 2006 HIGHEST RN 892389-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10748085b.str



chain nodes :

11 12 19 20 21 22 24 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18

chain bonds :

5-12 9-11 12-13 12-21 16-19 17-20 19-24 20-27 21-22 24-25 24-26

ring bonds :

1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

5-6 5-9 5-12 6-7 8-9 9-11 12-13 12-21 16-19 17-20 19-24 20-27 21-22 24-25 24-26

normalized bonds :

1-2 1-7 2-3 3-4 4-8 7-8 13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 : 13 :

G1:CH2,S02,C(O)CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d 11

07/13/2006 10748085b.trn

L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 08:03:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:03:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 48 TO ITERATE

100.0% PROCESSED 48 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.01

L3 25 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'HCAPLUS' ENTERED AT 08:03:41 ON 13 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2006 VOL 145 ISS 3
FILE LAST UPDATED: 12 Jul 2006 (20060712/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4

=> d 14 ibib abs hitstr tot

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:589381 HCAPLUS

DOCUMENT NUMBER: 141:140314

TITLE: Preparation of 2-(fluoroalkoxyphenylalkyl)-1,3-dihydroisoindolones as PDE4, TNF- α , and/or MMP inhibitors

INVENTOR(S): Muller, George W.; Man, Hon-Wah; Zhang, Weihong

PATENT ASSIGNEE(S): Celgene Corporation, USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060313	A2	20040722	WO 2003-US41568	20031229
WO 2004060313	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511843	AA	20040722	CA 2003-2511843	20031229
AU 2003303511	A1	20040729	AU 2003-303511	20031229
US 2004204448	A1	20041014	US 2003-748085	20031229
EP 1587474	A2	20051026	EP 2003-808605	20031229
EP 1587474	A3	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017885	A	20051206	BR 2003-17885	20031229
JP 2006515310	T2	20060525	JP 2004-565816	20031229
PRIORITY APPLN. INFO.:			US 2002-436975P	P 20021230
			WO 2003-US41568	W 20031229
OTHER SOURCE(S):			MARPAT 141:140314	
GI				



I



II


- AB Title compds. I [wherein X1-X4 = independently H, halo, NO₂, NH₂, CF₃, alkyl, cycloalkyl(alkyl), NR₇R₈-(alkyl), R₈CONH-(alkyl), NR₇R₈CONH-(alkyl), R₈OCONH-(alkyl), R₈O-(alkyl), imidazolyl(alkyl), pyrrolyl(alkyl), oxadiazolyl(alkyl), triazolyl(alkyl); or X1 and X2 or X2 and X3 or X3 and X4 may be taken together to form a (hetero)cycloalkyl ring; Y = CO, CH₂, CH₂CO, COCH₂, SO₂; Z = H, COR₃, alkylsulfonyl(alkyl), alkyl, CH₂OH, alkoxy, (un)substituted Ph, PhCH₂; R₄ and R₅ = independently H, alkyl, OH, alkoxy, (un)substituted Ph, PhCH₂; R₆ = alkyl(amino), Ph, PhCH₂, aryl; R₇ and R₈ = independently H, alkyl, cycloalkyl(alkyl), NR₇R₈-alkyl, R₈O-alkyl, Ph, PhCH₂, aryl; or pharmaceutically acceptable salts, hydrates, solvates, clathrates, stereoisomers, and prodrugs thereof] were prepared. For example, alkylation of 3,4-dihydroxybenzaldehyde with chlorodifluoromethane in the presence of K₂CO₃ in DMF gave 4-difluoromethoxy-3-hydroxybenzaldehyde (15%), which was further alkylated with bromomethylcyclopropane under the same conditions to afford 3-cyclopropylmethoxy-4-difluoromethoxybenzaldehyde (100%). Reaction of the benzaldehyde with ammonium acetate in 95% EtOH, followed by addition of malonic acid provided 3-amino-3-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)propionic acid (52%). Condensation of the amine with 3-acetamidophthalic anhydride using sodium acetate in AcOH yielded the isoindol-1-one II (85%). I and their pharmaceutical compns., optionally in combination with another therapeutic agent, are useful for the treatment or prevention of diseases associated with phosphodiesterase 4 (PDE4) inhibition, abnormal tumor necrosis factor α (TNF- α) levels, and/or matrix metalloproteinase (MMP) inhibition, such as myelodysplastic syndrome, myeloproliferative disease, complex regional pain syndrome, cancer, inflammatory diseases, and autoimmune diseases (no data).
- IT 725256-76-8P, 3-[3-(Cyclopropylmethoxy)-4-difluoromethoxyphenyl]-3-(7-nitro-1-oxo-1,3-dihydroisoindol-2-yl)propionic acid methyl ester
 725256-77-9P, 3-[3-(Cyclopropylmethoxy)-4-difluoromethoxyphenyl]-3-(7-nitro-1-oxo-1,3-dihydroisoindol-2-yl)propionic acid
 725256-78-0P, 3-[3-(Cyclopropylmethoxy)-4-difluoromethoxyphenyl]-3-

(7-nitro-1-oxo-1,3-dihydroisoindol-2-yl)-N,N-dimethylpropionamide
 725256-83-7P, 3-[7-(Cyclopropylcarbonylamino)-1-oxo-1,3-dihydroisoindol-2-yl]-3-(4-difluoromethoxy-3-ethoxyphenyl)propionic acid methyl ester 725256-84-8P, 3-(7-Amino-1-oxo-1,3-dihydroisoindol-2-yl)-3-(4-difluoromethoxy-3-ethoxyphenyl)propionic acid methyl ester 725256-85-9P, 3-(7-Acetylamino-1-oxo-1,3-dihydroisoindol-2-yl)-3-(4-difluoromethoxy-3-ethoxyphenyl)propionic acid methyl ester 725256-86-0P, 3-[7-(Acetylamino)-1-oxo-1,3-dihydroisoindol-2-yl]-3-(4-difluoromethoxy-3-ethoxyphenyl)propionic acid 725256-87-1P, 3-[7-(Cyclopropylcarbonylamino)-1-oxo-1,3-dihydroisoindol-2-yl]-3-(4-difluoromethoxy-3-ethoxyphenyl)propionic acid 725257-12-5P, 3-[3,4-Bis(difluoromethoxy)phenyl]-3-[7-(cyclopropylcarbonylamino)-1-oxo-1,3-dihydroisoindol-2-yl]propionic acid

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE4, TNF- α , and/or MMP inhibitor; preparation of (fluoroalkoxyphenylalkyl)isoindolones as PDE4, TNF- α , and/or MMP inhibitors for treatment of inflammatory diseases, autoimmune diseases, cancer, and pain)


RN 725256-76-8 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, β -[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-1,3-dihydro-7-nitro-1-oxo-, methyl ester (9CI)
 (CA INDEX NAME)




RN 725256-77-9 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, β -[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-1,3-dihydro-7-nitro-1-oxo- (9CI) (CA INDEX NAME)




RN 725256-78-0 HCAPLUS

CN 2H-Isoindole-2-propanamide, β -[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-1,3-dihydro-N,N-dimethyl-7-nitro-1-oxo- (9CI)
 (CA INDEX NAME)




RN 725256-83-7 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, 7-[(cyclopropylcarbonyl)amino]-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo-, methyl ester (9CI)
(CA INDEX NAME)




RN 725256-84-8 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, 7-amino-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 725256-85-9 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, 7-(acetylamino)-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo-, methyl ester (9CI) (CA INDEX NAME)





RN 725256-86-0 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, 7-(acetylamino)-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 725256-87-1 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, 7-[(cyclopropylcarbonyl)amino]-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 725257-12-5 HCAPLUS


CN 2H-Isoindole-2-propanoic acid, β-[3,4-bis(difluoromethoxy)phenyl]-7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)




IT 725256-79-1P, 3-(7-Amino-1-oxo-1,3-dihydroisoindol-2-yl)-3-[3-(cyclopropylmethoxy)-4-difluoromethoxyphenyl]-N,N-dimethylpropionamide
 725256-82-6P, 3-(4-Difluoromethoxy-3-ethoxyphenyl)-3-(7-nitro-1-oxo-1,3-dihydroisoindol-2-yl)propionic acid methyl ester
 725256-88-2P, Cyclopropanecarboxylic acid N-[2-[2-carbamoyl-1-(4-difluoromethoxy-3-ethoxyphenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide
 725256-89-3P, Cyclopropanecarboxylic acid N-[2-[1-(4-difluoromethoxy-3-ethoxyphenyl)-2-(dimethylcarbamoyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide 725256-90-6P, Cyclopropanecarboxylic acid N-[2-[1-(4-difluoromethoxy-3-ethoxyphenyl)-2-hydroxycarbamoyl]ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide
 725256-91-7P, 3-(7-Acetylamino-1-oxo-1,3-dihydroisoindol-2-yl)-3-(4-difluoromethoxy-3-ethoxyphenyl)propionamide 725256-92-8P, 3-(7-Acetylamino-1-oxo-1,3-dihydroisoindol-2-yl)-3-(4-difluoromethoxy-3-ethoxyphenyl)-N,N-dimethylpropionamide 725256-93-9P, 3-(7-Acetylamino-1-oxo-1,3-dihydroisoindol-2-yl)-3-(4-difluoromethoxy-3-ethoxyphenyl)-N-hydroxypropionamide 725257-02-3P, Cyclopropanecarboxylic acid N-[2-[2-carbamoyl-1-(4-difluoromethoxy-3-ethoxyphenyl)ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide
 725257-05-6P, N-[2-[1-(4-Difluoromethoxy-3-ethoxyphenyl)-3-(morpholin-4-yl)-3-oxopropyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]acetamide
 725257-08-9P, 3-[3,4-Bis(difluoromethoxy)phenyl]-3-[4-chloro-7-(cyclopropylcarbonylamino)-1-oxo-1,3-dihydroisoindol-2-yl]propionic acid methyl ester 725257-11-4P, Cyclopropanecarboxylic acid N-[2-[1-[3,4-bis(difluoromethoxy)phenyl]-2-(dimethylcarbamoyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide 725257-13-6P, Cyclopropanecarboxylic acid N-[2-[1-[3,4-bis(difluoromethoxy)phenyl]-2-carbamoyl]ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide
 725257-14-7P, Cyclopropanecarboxylic acid N-[2-[1-[3,4-bis(difluoromethoxy)phenyl]-2-hydroxycarbamoyl]ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (PDE4, TNF- α , and/or MMP inhibitor; preparation of (fluoroalkoxyphenylalkyl)isoindolones as PDE4, TNF- α , and/or MMP inhibitors for treatment of inflammatory diseases, autoimmune diseases, cancer, and pain)
 RN 725256-79-1 HCAPLUS
 CN 2H-Isoindole-2-propanamide, 7-amino- β -[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-1,3-dihydro-N,N-dimethyl-1-oxo- (9CI) (CA INDEX NAME)



RN 725256-82-6 HCAPLUS


CN 2H-Isoindole-2-propanoic acid, β -[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-7-nitro-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

RN 725256-88-2 HCAPLUS

CN 2H-Isoindole-2-propanamide, 7-[(cyclopropylcarbonyl)amino]- β -[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)


RN 725256-89-3 HCAPLUS

CN 2H-Isoindole-2-propanamide, 7-[(cyclopropylcarbonyl)amino]- β -[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-N,N-dimethyl-1-oxo- (9CI) (CA INDEX NAME)




RN 725256-90-6 HCAPLUS

CN 2H-Isoindole-2-propanamide, 7-[(cyclopropylcarbonyl)amino]-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-N-hydroxy-1-oxo- (9CI) (CA INDEX NAME)




RN 725256-91-7 HCAPLUS

CN 2H-Isoindole-2-propanamide, 7-(acetylamino)-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 725256-92-8 HCAPLUS

CN 2H-Isoindole-2-propanamide, 7-(acetylamino)-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-N,N-dimethyl-1-oxo- (9CI) (CA INDEX NAME)




RN 725256-93-9 HCAPLUS

CN 2H-Isoindole-2-propanamide, 7-(acetylamino)-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-N-hydroxy-1-oxo- (9CI) (CA INDEX NAME)




RN 725257-02-3 HCAPLUS

CN 2H-Isoindole-2-propanamide, 4-chloro-7-[(cyclopropylcarbonyl)amino]-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 725257-05-6 HCAPLUS

CN Acetamide, N-[2-[1-[4-(difluoromethoxy)-3-ethoxyphenyl]-3-(4-morpholinyl)-3-oxopropyl]-2,3-dihydro-3-oxo-1H-isoindol-4-yl]- (9CI) (CA INDEX NAME)




RN 725257-08-9 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, β -[3,4-bis(difluoromethoxy)phenyl]-4-chloro-7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 725257-11-4 HCAPLUS

CN 2H-Isoindole-2-propanamide, β -[3,4-bis(difluoromethoxy)phenyl]-7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-N,N-dimethyl-1-oxo- (9CI) (CA INDEX NAME)




RN 725257-13-6 HCAPLUS

CN 2H-Isoindole-2-propanamide, β -[3,4-bis(difluoromethoxy)phenyl]-7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)



RN 725257-14-7 HCAPLUS

CN 2H-Isoindole-2-propanamide, β-[3,4-bis(difluoromethoxy)phenyl]-7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-N-hydroxy-1-oxo- (9CI) (CA INDEX NAME)



IT 725257-03-4, 3-[4-Chloro-7-((cyclopropylcarbonyl)amino)-1-oxo-1,3-dihydroisoindol-2-yl]-3-(4-difluoromethoxy-3-ethoxyphenyl)propionic acid
725257-15-8, 3-[3,4-Bis(difluoromethoxy)phenyl]-3-[7-((cyclopropylcarbonyl)amino)-1-oxo-1,3-dihydroisoindol-2-yl]propionic acid methyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)



(preparation of (fluoroalkoxyphenylalkyl)isoindolones as PDE4, TNF-α, and/or MMP inhibitors for treatment of inflammatory diseases, autoimmune diseases, cancer, and pain)

RN 725257-03-4 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, 4-chloro-7-[(cyclopropylcarbonyl)amino]-β-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,3-dihydro-1-oxo- (9CI) (CA INDEX NAME)


07/13/2006

10748085b.trn



RN 725257-15-8 HCAPLUS

CN 2H-Isoindole-2-propanoic acid, β -[3,4-bis(difluoromethoxy)phenyl]-7-
 [(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-, methyl ester (9CI) (CA
 INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.17	177.32

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 08:04:56 ON 13 JUL 2006